Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary fusion: A case report and literature review.

gene has been identified as an oncogenic driver and a potential target in various malignancies. fusions are one subtype of alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with fusion who achieves partial response to the MAK inhibitor trametinib. We also provide a literature review on targeted therapies for fusions.